| Year |
Citation |
Score |
| 2022 |
Bota DA, Taylor TH, Lomeli N, Kong XT, Fu BD, Schönthal AH, Singer S, Blumenthal DT, Senecal FM, Linardou H, Rokas E, Antoniou DG, Schijns VEJC, Chen TC, Elliot J, et al. A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. Frontiers in Oncology. 12: 934638. PMID 35837107 DOI: 10.3389/fonc.2022.934638 |
0.32 |
|
| 2020 |
Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, et al. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. Jama Oncology. PMID 33119048 DOI: 10.1001/jamaoncol.2020.3161 |
0.309 |
|
| 2020 |
Mirian C, Duun-Henriksen AK, Maier AD, Pedersen MM, Jensen LR, Bashir A, Graillon T, Hrachova M, Bota D, van Essen M, Spanjol P, Kreis C, Law I, Broholm H, Poulsgaard L, et al. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: an individual patient data meta-analysis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32859705 DOI: 10.2967/Jnumed.120.249607 |
0.372 |
|
| 2020 |
Hrachova M, Nguyen ENT, Fu BD, Dandekar MJ, Kong XT, Cadena G, Hsu FPK, Billimek J, Taylor TH, Bota DA. A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas. Frontiers in Neurology. 11: 373. PMID 32435228 DOI: 10.3389/Fneur.2020.00373 |
0.431 |
|
| 2020 |
Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, et al. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32034072 DOI: 10.1158/1078-0432.Ccr-18-1140 |
0.364 |
|
| 2019 |
Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, Liau LM, Buckner JC, Weller M, Berger MS, Glantz M. Management of low-grade glioma: a systematic review and meta-analysis. Neuro-Oncology Practice. 6: 249-258. PMID 31386075 DOI: 10.1093/Nop/Npy034 |
0.339 |
|
| 2019 |
Mason WP, Kesari S, Stupp R, Aregawi DG, Piccioni DE, Roth P, Desjardins A, Reich SD, Casadebaig M, Elias I, Winograd B, Levin N, Bota DA. Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 37: 2021-2021. DOI: 10.1200/Jco.2019.37.15_Suppl.2021 |
0.363 |
|
| 2019 |
Bota DA, Di K, Keator DB, Bota RG, Hoffmann M, Dumitru CD, Levin N. Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain Cancer Research. 79: 4733-4733. DOI: 10.1158/1538-7445.Am2019-4733 |
0.312 |
|
| 2019 |
Cloughesy T, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu J, Iwamoto F, Placantonakis D, Martinez N, Elder JB, Kaptain G, et al. LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 21: vi284-vi284. DOI: 10.1093/Neuonc/Noz219.1199 |
0.373 |
|
| 2019 |
Bota D, Taylor T, Picconi D, Duma C, Aiken R, LaRocca R, Xiao-Tang K, Fu B, Alsharif M, Hsieh C, Nistor G, Dillman R. Atim-28. Phase Ii Trial Of Av-Gbm-1 (Autologous Dendritic Cells Loaded With Tumor Associated Antigens) As Adjunctive Therapy Following Surgery Plus Concurrent Chemoradiation In Newly Diagnosed Gbm Patients Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.027 |
0.369 |
|
| 2018 |
Lomeli N, Bota DA. Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic. Translational Cancer Research. 7: 6215-6226. PMID 31840022 DOI: 10.21037/Tcr.2018.03.05 |
0.422 |
|
| 2018 |
Di K, Lomeli N, Bota DA, Das BC. Magmas inhibition as a potential treatment strategy in malignant glioma. Journal of Neuro-Oncology. PMID 30414099 DOI: 10.1007/S11060-018-03040-8 |
0.303 |
|
| 2018 |
Yan H, Romero-López M, Benitez LI, Di K, Frieboes HB, Hughes CCW, Bota DA, Lowengrub JS. Multiscale modeling of glioblastoma. Translational Cancer Research. 7: S96-S98. PMID 30211018 DOI: 10.21037/Tcr.2017.12.10 |
0.308 |
|
| 2018 |
Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts. Cns Oncology. PMID 30157683 DOI: 10.2217/Cns-2018-0009 |
0.376 |
|
| 2018 |
Schijns VEJC, Pretto C, Strik AM, Gloudemans-Rijkers R, Deviller L, Pierre D, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FPK, Hofman FM, Chen TC, Zidovetzki R, ... Bota DA, et al. Therapeutic Immunization against Glioblastoma. International Journal of Molecular Sciences. 19. PMID 30150597 DOI: 10.3390/Ijms19092540 |
0.42 |
|
| 2018 |
Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, ... ... Bota DA, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 142. PMID 29843811 DOI: 10.1186/S12967-018-1507-6 |
0.341 |
|
| 2018 |
Pham JT, Kim RC, Nguyen A, Bota D, Kong XT, Vadera S, Hsu F, Carrillo JA. Intracranial meningioma with carcinoma tumor-to-tumor metastasis: two case reports. Cns Oncology. PMID 29698064 DOI: 10.2217/Cns-2017-0022 |
0.337 |
|
| 2018 |
Bota DA, Kesari S, Piccioni DE, Aregawi DG, Roth P, Stupp R, Desjardins A, Reich SD, Elias I, Li M, Levin N, Winograd B, Mason WP. A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E14083 |
0.375 |
|
| 2018 |
Tran D, Kesari S, Bota DA. Qolp-15. Safety And Adverse Event Profile Of Tumor Treating Fields In Anaplastic Glioma A Post-Marketing Surveillance Analysis Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.901 |
0.302 |
|
| 2018 |
Bajwa S, Flanagan L, Hernandez S, Fu DB, Bota D, Kong X. Path-06. Quantitative Analysis Of Mgmt Promoter Methylation And Its Prognostic Value In Glioblastoma Multiforme (Gbm) Patients Treated With Alkylating Chemotherapy- Preliminary Report Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.662 |
0.307 |
|
| 2018 |
Bota DA, Kesari S, Piccioni D, Aregawi D, Roth P, Stupp R, Desjardins A, Reich SD, Elias I, Li M, Levin N, Winograd B, Mason W. ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.073 |
0.36 |
|
| 2018 |
Kong X, Lai A, Carrillo JA, Fu DB, Meyskens F, Bota DA. Actr-10. A Randomized, Phase I/Ii Trial Of Ixazomib In Combination With Standard Therapy For Upfront Treatment Of Patients With Newly Diagnosed Mgmt Methylated Glioblastoma (Gbm) Study Design Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.045 |
0.33 |
|
| 2017 |
Yan H, Romero-López M, Benitez LI, Di K, Frieboes HB, Hughes CCW, Bota DA, Lowengrub JS. 3D mathematical modeling of glioblastoma suggests that transdifferentiated vascular endothelial cells mediate resistance to current standard-of-care therapy. Cancer Research. PMID 28536277 DOI: 10.1158/0008-5472.Can-16-3094 |
0.364 |
|
| 2017 |
Majd P, O'Connell DE, Kim RC, Bota DA, Carrillo JA. Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma. Cns Oncology. PMID 28303729 DOI: 10.2217/Cns-2016-0035 |
0.394 |
|
| 2017 |
Brown TJ, Bota DA, Maher EA, Aregawi DG, Liau LM, Brown PD, Buckner JC, Weller M, Van Den Bent MJ, Berger MS, Glantz MJ. Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A systematic review and meta-analysis of numbers needed to treat. Journal of Clinical Oncology. 35: 2057-2057. DOI: 10.1200/Jco.2017.35.15_Suppl.2057 |
0.353 |
|
| 2017 |
Brown TJ, Bota DA, Maher EA, Aregawi DG, Liau LM, Brown PD, Buckner JC, Weller M, Van Den Bent MJ, Berger MS, Glantz MJ. Association of aggressive resection with survival and progression-free survival in adult low-grade glioma: A systematic review and meta-analysis with numbers needed to treat. Journal of Clinical Oncology. 35: 2025-2025. DOI: 10.1200/Jco.2017.35.15_Suppl.2025 |
0.35 |
|
| 2017 |
Chang P, Bota DA, Filippi C, Chow D. Nimg-89. Deep Learning Approaches To Identify Intra-Tumoral Heterogeneity Of Low And High Grade Gliomas Neuro-Oncology. 19: 162-162. DOI: 10.1093/Neuonc/Nox168.658 |
0.308 |
|
| 2017 |
Nguyen E, Fu B, Dandekar M, Carrillo J, Kong X, Cadena G, Hsu FP, Billimek J, Bota D. Mngi-12. A Retrospective Interventional Cohort Study To Assess The Efficacy And Safety Of Sandostatin Lar (Octreotide Acetate) For The Treatment Of Meningiomas In Adult Patients Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.550 |
0.422 |
|
| 2017 |
Bota DA, Lomeli N, Di K, Das B. Exth-85. Magmas Inhibition As A Potential Treatment Strategy In Malignant Glioma Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.375 |
0.315 |
|
| 2017 |
Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aquirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T. ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE Neuro-Oncology. 19: vi30-vi31. DOI: 10.1093/Neuonc/Nox168.116 |
0.347 |
|
| 2017 |
Bota D, Desjardins A, Mason W, Kesari S, Magge R, Winograd B, Reich SD, Levin N, Trikha M. Actr-71. Full Enrollment Results From The Phase 1/2, Multicenter, Open-Label Study Of Marizomib (Mrz) ± Bevacizumab (Bev) In Recurrent Who Grade Iv Malignant Glioma (Glioblastoma, Rgbm) Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.058 |
0.321 |
|
| 2017 |
Bota D, Mason W, Kesari S, Piccioni D, Aregawi D, Desjardins A, Winograd B, Reich SD, Levin N, Trikha M. ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM) Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.036 |
0.357 |
|
| 2017 |
O’Connell D, Shen V, Loudon W, Bota D. Hgg-13. First Report Of Tumor Treating Fields Use In Combination With Bevacizumab In A Pediatric Patient Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox083.102 |
0.357 |
|
| 2016 |
O'Connell D, Shen V, Loudon W, Bota DA. First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report. Cns Oncology. PMID 27918194 DOI: 10.2217/Cns-2016-0018 |
0.407 |
|
| 2016 |
Di K, Lomeli N, Wood SD, Vanderwal CD, Bota DA. Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma. Oncotarget. PMID 27764809 DOI: 10.18632/Oncotarget.12681 |
0.357 |
|
| 2016 |
Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, Damek D, Bota DA, Connelly J. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. Cns Oncology. PMID 27628854 DOI: 10.2217/Cns-2016-0032 |
0.388 |
|
| 2016 |
Nolen SC, Lee B, Shantharam S, Yu HJ, Su L, Billimek J, Bota DA. The effects of sequential treatments on hippocampal volumes in malignant glioma patients. Journal of Neuro-Oncology. PMID 27393350 DOI: 10.1007/S11060-016-2188-8 |
0.379 |
|
| 2016 |
Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A, Trikha M, Bota DA. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro-Oncology. 18: 840-8. PMID 26681765 DOI: 10.1200/Jco.2015.33.15_Suppl.E12644 |
0.345 |
|
| 2016 |
Dunbar EM, Iwamoto FM, Trusheim JE, Mohile N, Battiste J, Connelly JM, Damek D, Bota DA. Development of practice algorithms to guide treatment planning with TTFields for the management of glioblastoma (GB). Journal of Clinical Oncology. 34: e13519-e13519. DOI: 10.1200/Jco.2016.34.15_Suppl.E13519 |
0.36 |
|
| 2016 |
Bota DA, Desjardins A, Mason WP, Fine HA, Reich SD, Trikha M. Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG). Journal of Clinical Oncology. 34: 2037-2037. DOI: 10.1200/Jco.2016.34.15_Suppl.2037 |
0.341 |
|
| 2016 |
Lomeli N, Czerniawski J, Di K, Guzowski J, Bota D. Abstract 4782: Cisplatin induces mitochondrial damage and hippocampal neurotoxicity: a potential mechanism for chemotherapy-related cognitive impairment Cancer Research. 76: 4782-4782. DOI: 10.1158/1538-7445.Am2016-4782 |
0.311 |
|
| 2016 |
Bota D, Desjardins A, Mason W, Di K, MacLaren AP, Levin N, Trikha M. Abstract 3069: Investigation of pharmacodynamic and predictive biomarkers to define response to proteasome inhibitor marizomib in glioma Cancer Research. 76: 3069-3069. DOI: 10.1158/1538-7445.Am2016-3069 |
0.334 |
|
| 2016 |
Bota D, Carrillo J, Kong X, Fu D, Chung J, Pretto C, Strik A, Schijns V, Stathopoulos A. Atim-20. A Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study Of The Erc-1671 (Gliovac) Vaccine In Combination With Bevacizumab (Bev) In Recurrent Gbm Patients: Safety Lead-In Analysis Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.085 |
0.3 |
|
| 2016 |
Aghi M, Vogelbaum M, Kalkanis S, Bota D, Carter B, Chen C, Elder B, Engh J, Goldlust S, Kaptain G, Kesari S, Landolfi J, Liau L, Mikkelsen T, Piccioni D, et al. ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL Neuro-Oncology. 18: vi18-vi18. DOI: 10.1093/Neuonc/Now212.070 |
0.316 |
|
| 2016 |
Cloughesy T, Walbert T, Bota D, Vogelbaum M, Liau L, Ostertag D, Jolly D, Gruber H, Yang L, Shorr J, Kalkanis S. ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) Neuro-Oncology. 18: vi17-vi17. DOI: 10.1093/Neuonc/Now212.067 |
0.307 |
|
| 2016 |
Bota D, Desjardins A, Mason W, Fine H, Kesari S, Reich SD, Vashishtha A, Levin N, Trikha M. Actr-50. Marizomib (Mrz) With Bevacizumab (Bev) In Who Grade Iv Malignant Glioma (G4 Mg): Full Enrollment Results From The Phase 1, Multicenter, Open-Label Study Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.048 |
0.303 |
|
| 2016 |
O’Connell D, Carrillo J, Kong X, Fu B, Bota D. Actr-41. A Phase Ii, Single Arm Study Of Optune® In Bevacizumab-Naive Subjects With Recurrent Who Grade Iii Malignant Glioma Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.039 |
0.311 |
|
| 2015 |
Reardon DA, Schuster JM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, et al. 107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. Neurosurgery. 62: 198-199. PMID 26181953 DOI: 10.1227/01.Neu.0000467069.86811.3F |
0.388 |
|
| 2015 |
Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine. 33: 2690-6. PMID 25865468 DOI: 10.1016/J.Vaccine.2015.03.095 |
0.445 |
|
| 2015 |
Bota DA, Alexandru-Abrams D, Pretto C, Hofman FM, Chen TC, Fu B, Carrillo JA, Schijns VE, Stathopoulos A. Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. The Permanente Journal. 19: 41-6. PMID 25785641 DOI: 10.7812/Tpp/14-042 |
0.376 |
|
| 2015 |
Abrams DA, Hanson JA, Brown JM, Hsu FP, Delashaw JB, Bota DA. Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 22: 35-9. PMID 25481268 DOI: 10.1016/J.Jocn.2014.05.054 |
0.32 |
|
| 2015 |
Reardon DA, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, et al. ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Journal of Clinical Oncology. 33: 2009-2009. DOI: 10.1200/Jco.2015.33.15_Suppl.2009 |
0.313 |
|
| 2015 |
Reardon DA, Desjardins A, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Werner A, Vitale L, He Y, et al. IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov218.08 |
0.363 |
|
| 2014 |
Mrugala MM, Engelhard HH, Butowski N, Tran DD, Kew Y, Cavaliere R, Villano J, Bota D, Kesari S, Rudnick J, Sumrall A, Zhu JJ, Wong ET. 415OALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA - NOVOTTF-100A SYSTEM: UPDATED OUTCOMES AND TOXICITY BASED ON THE ANALYSIS OF PATIENT REGISTRY DATA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv137. PMID 28170762 DOI: 10.1093/Annonc/Mdu330.2 |
0.353 |
|
| 2014 |
Paff M, Alexandru-Abrams D, Hsu FP, Bota DA. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Human Vaccines & Immunotherapeutics. 10: 3322-31. PMID 25625931 DOI: 10.4161/21645515.2014.983002 |
0.382 |
|
| 2014 |
Alexandru-Abrams D, Jadus MR, Hsu FP, Stathopoulos A, Bota DA. Therapeutic targeting of malignant glioma. Anti-Cancer Agents in Medicinal Chemistry. 14: 1075-84. PMID 25175690 DOI: 10.2174/1871520614666140825105145 |
0.395 |
|
| 2014 |
Di K, Keir ST, Alexandru-Abrams D, Gong X, Nguyen H, Friedman HS, Bota DA. Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. Journal of Neuro-Oncology. 120: 473-81. PMID 25115740 DOI: 10.1007/S11060-014-1579-Y |
0.346 |
|
| 2014 |
Carrillo JA, Hsu FPK, Delashaw J, Bota D. Efficacy and safety of bevacizumab and etoposide combination in patients with recurrent malignant gliomas who have failed bevacizumab Reviews in Health Care. 5: 23-32. DOI: 10.7175/Rhc.V5I1.668 |
0.442 |
|
| 2014 |
Wong ET, Engelhard HH, Tran DD, Kew Y, Mrugala MM, Cavaliere R, Villano JL, Bota DA, Rudnick J, Sumrall AL, Zhu J. NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma: An analysis of patient registry data. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E13033 |
0.31 |
|
| 2014 |
Di K, Gong X, Curticiu DM, Palladino MA, Bota DA. Abstract 1809: Marizomib (NPI-0052) activity as a single agent in malignant glioma Cancer Research. 74: 1809-1809. DOI: 10.1158/1538-7445.Am2014-1809 |
0.394 |
|
| 2014 |
Majd P, O'Connell D, Kim R, Bota D, Carrillo J. RM-05CASE OF GLIOBLASTOMA PATIENT TREATED WITH NovoTTF THERAPY AT RECURRENCE DEGENERATING TO SARCOMA Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou273.5 |
0.407 |
|
| 2014 |
Fu DB, Bota DA. Rh-01The Significance Of Acute Inpatient Rehabilitation For Glioma Patients: Improving The Physical Function, Quality Of Life And Survival Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou272.1 |
0.348 |
|
| 2014 |
Schijns V, Pretto C, Devillers L, Pierre D, Hofman F, Kruse C, Chen T, Oertel J, Hantos P, Bota D, Stathopoulos A. ET-54 * IMMUNOTHERAPY BASED ON TUMOR TRANSPLANT ANTIGEN RECOGNITION EMERGES AS A PROMISING STRATEGY FOR RECURRENT GLIOBLASTOMA MULTIFORME (GBM) PATIENTS Neuro-Oncology. 16: v90-v91. DOI: 10.1093/Neuonc/Nou255.51 |
0.432 |
|
| 2014 |
Di K, Gong X, Nguyen H, Trikha M, Bota D. Et-16Marizomib (Npi-0052) Activity As A Single Agent In Malignant Glioma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou255.16 |
0.381 |
|
| 2014 |
Wong ET, Engelhard HH, Tran DD, Kew Y, Mrugala MM, Cavaliere R, Villano JL, Bota DA, Rudnick J, Sumrall AL, Zhu JJ. Ed-38An Updated Analysis Of Patient Registry Data On Novottf-100A Alternating Electric Fields Therapy For Recurrent Glioblastoma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou253.38 |
0.366 |
|
| 2013 |
Hanson JA, Hsu FP, Jacob AT, Bota DA, Alexandru D. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme. The Permanente Journal. 17: 68-74. PMID 24361023 DOI: 10.7812/Tpp/13-081 |
0.378 |
|
| 2013 |
Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. Journal of Neurosurgery. 119: 1415-23. PMID 24093630 DOI: 10.3171/2013.7.Jns1323 |
0.335 |
|
| 2013 |
Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. Journal of Neurosurgery. 118: 1183-7. PMID 23451905 DOI: 10.3171/2013.1.Jns12397 |
0.36 |
|
| 2013 |
Di K, Linskey ME, Bota DA. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. Oncogene. 32: 5038-5047. PMID 23178488 DOI: 10.1038/Onc.2012.531 |
0.372 |
|
| 2013 |
Alexandru D, Kao H, Linskey M, Kim R, Hasso AN, Bota D. Recurrent Glioblastoma Multiforme: Implication of Nonenhancing Lesions on Bevacizumab Treatment Journal of Interdisciplinary Histopathology. 1: 217-222. DOI: 10.5455/Jihp.20130328081943 |
0.383 |
|
| 2013 |
Alexandru D, Linskey ME, Kim RC, Bota D. Undifferentiated Sarcoma Induced by BCNU (1,3-bis(2-chloroethyl) -1-nitrosourea) Wafers - Journal of Interdisciplinary Histopathology. 1: 163-167. DOI: 10.5455/Jihp.20130116012102 |
0.386 |
|
| 2012 |
Alexandru D, Bota DA, Linskey ME. Epidemiology of central nervous system metastases. Progress in Neurological Surgery. 25: 13-29. PMID 22236665 DOI: 10.1159/000331167 |
0.341 |
|
| 2012 |
Nashed M, Glantz MJ, Linskey ME, Bota DA. Access to specialized treatment by adult Hispanic brain tumor patients: findings from a single-institution retrospective study Community Oncology. 9: 283-288. DOI: 10.1016/J.Cmonc.2012.06.005 |
0.359 |
|
| 2011 |
Bota DA, Eroglu Z, Reardon DA, Fu BD, Norfleet J, Desjardins A, Linskey ME, Peters K, Friedman HS, Vredenburgh JJ. Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2056. PMID 28019947 DOI: 10.1200/Jco.2011.29.15_Suppl.2056 |
0.376 |
|
| 2011 |
Alexandru D, Glantz MJ, Kim L, Chamberlain MC, Bota DA. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging. Cancer. 117: 4506-11. PMID 21446045 DOI: 10.1002/Cncr.26065 |
0.335 |
|
| 2011 |
Gong X, Schwartz PH, Linskey ME, Bota DA. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 76: 1126-34. PMID 21346220 DOI: 10.1212/Wnl.0B013E318212A89F |
0.334 |
|
| 2010 |
Ge L, Hoa N, Bota DA, Natividad J, Howat A, Jadus MR. Immunotherapy of brain cancers: the past, the present, and future directions. Clinical & Developmental Immunology. 2010: 296453. PMID 21437175 DOI: 10.1155/2010/296453 |
0.35 |
|
| 2010 |
Alexandru D, Van Horn DK, Bota DA. Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib. Journal of Neuro-Oncology. 99: 123-8. PMID 20043189 DOI: 10.1007/S11060-009-0096-X |
0.366 |
|
| 2009 |
Bota DA, Dafer RM. Acute methotrexate neurotoxicity with choreiform movements and focal neurological deficits: a case report. Southern Medical Journal. 102: 1071-4. PMID 19738521 DOI: 10.1097/Smj.0B013E3181B66B28 |
0.305 |
|
| 2007 |
Bota DA, Desjardins A, Quinn JA, Affronti ML, Friedman HS. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Therapeutics and Clinical Risk Management. 3: 707-15. PMID 18472995 |
0.313 |
|
| 2007 |
Bota DA, Desjardins A, Quinn JA, Rich JN, Vredenburgh JJ, Sathornsumetee S, Goli K, Salvado A, Friedman HS, Reardon DA. Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma Journal of Clinical Oncology. 25: 2053-2053. DOI: 10.1200/Jco.2007.25.18_Suppl.2053 |
0.373 |
|
| 2007 |
Goli KJ, Desjardins A, Herndon JE, Rich JN, Reardon DA, Quinn JA, Sathornsumetee S, Bota DA, Friedman HS, Vredenburgh JJ. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas Journal of Clinical Oncology. 25: 2003-2003. DOI: 10.1200/Jco.2007.25.18_Suppl.2003 |
0.399 |
|
| 2007 |
Bohlin CW, Reardon DA, Desjardins A, Quinn JA, Rich JN, Bota DA, Goli K, Friedman HS, Vredenburgh JJ. Tinzaparin prophylaxis in brain tumor patients Journal of Clinical Oncology. 25: 12506-12506. DOI: 10.1200/Jco.2007.25.18_Suppl.12506 |
0.35 |
|
| Show low-probability matches. |